Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
| Revenue (TTM) | $8.31B |
| Gross Profit (TTM) | $4.55B |
| EBITDA | $1.14B |
| Operating Margin | 9.78% |
| Return on Equity | 34.00% |
| Return on Assets | 2.70% |
| Revenue/Share (TTM) | $47.79 |
| Book Value | $28.22 |
| Price-to-Book | 3.13 |
| Price-to-Sales (TTM) | 1.76 |
| EV/Revenue | 2.398 |
| EV/EBITDA | 8.08 |
| Quarterly Earnings Growth (YoY) | 3.90% |
| Quarterly Revenue Growth (YoY) | 2.20% |
| Shares Outstanding | $170.22M |
| Float | $144.09M |
| % Insiders | 15.34% |
| % Institutions | 76.17% |
Volatility is currently expanding
EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow allocation.
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Solventum (SOLV) reported earnings 30 days ago. What's next for the stock?
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SOLV and any ticker you trade — then tracks every position and per-strategy win rate.
